Hallucinogens and serotonergic mechanisms
- PMID: 1435968
Hallucinogens and serotonergic mechanisms
Abstract
Classical hallucinogens possess 5-HT2 agonist activity; certain structurally related agents are antagonists, but there is no evidence that the antagonists are hallucinogenic. Both the discriminative stimulus and human hallucinogenic potencies of the agonists are significantly correlated with 5-HT2 receptor affinity when [3H]-ketanserin is used as radioligand (Glennon et al., 1984). These agents appear to bind with higher affinity when [3H]DOB, an agent that apparently labels the agonist high-affinity state of 5-HT2 receptors, is used as radioligand (Sadzot et al., 1989). For a series of DOB-related agents, 5-HT2(KET) affinity can be modeled by the lipophilicity of the 4-position substituent; lipophilicity alone does not completely account for the affinity of 5-HT2 agonists. Using [3H]DOB as radioligand to minimize differences observed between agonists and antagonists, 5-HT2 affinity is related both to the lipophilicity and electron withdrawing nature of the 4-position substituents. The difference between 5-HT2(KET) and 5-HT2(DOB) binding may be related to the intrinsic activity of DOB-related agents. Serotonin, with an intrinsic activity of 1.0, is not hallucinogenic whereas hallucinogens may be hallucinogenic because they are high-affinity 5-HT2 partial agonists.
Similar articles
-
3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors.Mol Pharmacol. 1987 Feb;31(2):194-9. Mol Pharmacol. 1987. PMID: 3543649
-
[3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor.Mol Pharmacol. 1990 Nov;38(5):604-9. Mol Pharmacol. 1990. PMID: 2233697
-
(R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes.Mol Pharmacol. 1988 Oct;34(4):537-42. Mol Pharmacol. 1988. PMID: 3173334
-
Discriminative stimulus properties of hallucinogens and related designer drugs.NIDA Res Monogr. 1991;(116):25-44. NIDA Res Monogr. 1991. PMID: 1369672 Review.
-
Do classical hallucinogens act as 5-HT2 agonists or antagonists?Neuropsychopharmacology. 1990 Oct-Dec;3(5-6):509-17. Neuropsychopharmacology. 1990. PMID: 2078284 Review.
Cited by
-
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.Pharmacol Rev. 2021 Jan;73(1):310-520. doi: 10.1124/pr.118.015552. Pharmacol Rev. 2021. PMID: 33370241 Free PMC article. Review.
-
Role of the 5-HT₂A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice.Neuropharmacology. 2013 Jul;70:218-27. doi: 10.1016/j.neuropharm.2013.01.014. Epub 2013 Jan 29. Neuropharmacology. 2013. PMID: 23376711 Free PMC article.
-
The unique neural signature of your trip: Functional connectome fingerprints of subjective psilocybin experience.Netw Neurosci. 2024 Apr 1;8(1):203-225. doi: 10.1162/netn_a_00349. eCollection 2024. Netw Neurosci. 2024. PMID: 38562294 Free PMC article.
-
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.Neuropharmacology. 2011 Sep;61(3):364-81. doi: 10.1016/j.neuropharm.2011.01.017. Epub 2011 Jan 20. Neuropharmacology. 2011. PMID: 21256140 Free PMC article. Review.
-
Agonistic properties of cannabidiol at 5-HT1a receptors.Neurochem Res. 2005 Aug;30(8):1037-43. doi: 10.1007/s11064-005-6978-1. Neurochem Res. 2005. PMID: 16258853
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources